chosen keywordFocal-onset seizures
A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.
Trinka, E; Tsong, W; Toupin, S; Patten, A; Wilson, K; Isojarvi, J; James, D
EPILEPSY RES. 2020; 166: 106403
Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis.
Lattanzi, S; Zaccara, G; Giovannelli, F; Grillo, E; Nardone, R; Silvestrini, M; Trinka, E; Brigo, F;
Acta Neurol Scand. 2019; 139(1): 33-41.
Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger, C; Koepp, M; Trinka, E; Villanueva, V; Chaves, J; Ben-Menachen, E; Kowacs, PA; Gil-Nagel, A; Moreira, J; Gama, H; Rocha, JF; Soares-da-Silva, P
CNS NEUROSCI THER. 2017; 23(12): 961-972.
Full papers/articles (Journal)
Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon, SD; Trinka, E; Steinhoff, BJ; Holtkamp, M; Villanueva, V; Peltola, J; Ben-Menachem, E;
J Neurol. 2017; 264(3): 42-431.